目的 探討寧泌泰膠囊聯(lián)合注射用頭孢哌酮鈉舒巴坦鈉治療急性腎盂腎炎的臨床療效。方法 選取2015年2月—2016年2月武漢市黃陂區(qū)人民醫(yī)院收治的急性腎盂腎炎患者84例，按照隨機(jī)數(shù)字表法分為對照組和治療組，每組各42例。對照組靜脈滴注注射用頭孢哌酮鈉舒巴坦鈉，1.5 g加入到生理鹽水100 mL中，2次/d。治療組在對照組基礎(chǔ)上口服寧泌泰膠囊，4粒/次，3次/d。兩組患者連續(xù)治療2周。觀察兩組的臨床療效，比較兩組的腎功能和腎間質(zhì)纖維化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為76.19%、92.86%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組血尿素氮（BUN）、血肌酐（Scr）和微量白蛋白（MAU）水平均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組血清轉(zhuǎn)化生長因子β₁（TGF-β₁）和基質(zhì)金屬蛋白酶抑制劑-1（TIMP-1）水平均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 寧泌泰膠囊聯(lián)合注射用頭孢哌酮鈉舒巴坦鈉具有較好的臨床療效，能明顯改善患者腎功能，降低腎間質(zhì)纖維化，具有一定的臨床推廣價(jià)值。

Objective To evaluate the clinical effect of Ningmitai Capsules combined with Cefoperazone Sodium and Sulbactam Sodium for injection in treatment of acute pyelonephritis. Methods Patients (84 cases) with acute pyelonephritis in Huangpi District People's Hospital of Wuhan from February 2015 to February 2016 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 1.5 g added into normal saline 100 mL, twice daily. Patients in the treatment group were po administered with Ningmitai Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and renal function and renal interstitial fibrosis in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.19% and 92.86%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of BUN, Scr, and MAU in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TGF-β₁ and TIMP-1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ningmitai Capsules combined with Cefoperazone Sodium and Sulbactam Sodium for injection has clinical curative effect in treatment of acute pyelonephritis, can improve renal function, and decrease renal interstitial fibrosis, which has a certain clinical application value.